PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 27, 2026Science Translational Medicine

Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlexander ArnukCHCuijuan HanALAbimbola Eunice. Lawal

Discussion

Loading...

Member takes

Overview

Identifies KDM4 inhibition as a strategy to reactivate ZBTB7A in acute myeloid leukemia, suggesting a new therapeutic pathway.

Key Points

  • The aim is to explore the reactivation of the tumor suppressor ZBTB7A through KDM4 inhibition in acute myeloid leukemia.
  • Identified ZBTB7A as down-regulated in AML samples and associated with poor survival.
  • Developed a CRISPR-based screening approach combined with fluorescence in situ hybridization and flow cytometry.
  • Examined the effects of KDM4 inhibition on ZBTB7A expression and AML progression in patient-derived models.
  • KDM4 inhibition up-regulated ZBTB7A expression in AML cells.
  • Pharmacologic inhibition promoted terminal differentiation in xenograft models.
  • Demonstrated broad antileukemic efficacy while preserving normal blood cell production.

Cite This Study

Arnuk et al. (2026) studied this question.

synapsesocial.com/papers/69a13571ed1d949a99abf452https://doi.org/10.1126/scitranslmed.ady2936
View Full Paper
Ask AI
Bookmark
Share